MDXH (MDxHealth) Other Current Payables: $0.0 Mil (As of Mar. 2026)


MDXH MDxHealth SA MDXH
49 GF Score
Price $0.48
GF Value $2.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MDxHealth Other Current Payables?

MDxHealth MDXH -2.76% 49 Other Current Payables is $0.0 Mil as of Mar. 2026. GuruFocus rates MDXH with a GF Score™ of 49/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

MDxHealth's Other Current Payables for the quarter that ended in Mar. 2026 was $0.0 Mil.

MDxHealth Other Current Payables Related Terms

MDxHealth Other Current Payables Historical Data

* Premium members only.

The historical data trend for MDxHealth's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MDxHealth Other Current Payables Chart

MDxHealth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MDxHealth Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDXH
49GF Score
MDxHealth SA MDXH
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MDxHealth Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.0 Mil mean?
MDxHealth (MDXH) has a Other Current Payables of $0.0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on MDxHealth and its competitors.
Is MDxHealth's Other Current Payables too high?
MDxHealth's current Other Current Payables is $0.0 Mil. Overall, MDxHealth has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Other Current Payables compare to AWHL and BIOQ?
MDxHealth's Other Current Payables of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Diagnostics & Research company?
A good Other Current Payables depends on the Medical Diagnostics & Research industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on MDxHealth and its competitors. MDxHealth's current Other Current Payables is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.48 — trading 78.4% below its estimated fair value. The current Other Current Payables is $0.0 Mil. MDxHealth's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For MDxHealth (MDXH), the current Other Current Payables is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MDxHealth (MDXH) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of $0.48 is trading 78.4% below its estimated GF Value™ of $2.20. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for MDXH:

  • Other Current Payables: $0.0 Mil
  • GF Value™: $2.20 vs. price of $0.48 (78.4% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MDxHealth Business Description

Other Exchanges O6C1:Germany
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
49GF Score

Get the complete analysis for MDXH

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price
$2.20
GF Value